MARKET

CARM

CARM

Carisma Therapeutics Inc
NASDAQ
0.4000
+0.0020
+0.50%
Pre Market: 0.4000 0 0.00% 04:14 07/14 EDT
OPEN
0.3980
PREV CLOSE
0.3980
HIGH
0.4100
LOW
0.3870
VOLUME
1.11K
TURNOVER
0
52 WEEK HIGH
1.380
52 WEEK LOW
0.1417
MARKET CAP
16.72M
P/E (TTM)
-0.3283
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CARM last week (0707-0711)?
Weekly Report · 5h ago
Weekly Report: what happened at CARM last week (0630-0704)?
Weekly Report · 07/07 09:44
Weekly Report: what happened at CARM last week (0623-0627)?
Weekly Report · 06/30 09:46
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 06/23 21:06
Carisma Therapeutics Announces Merger with OrthoCellix
TipRanks · 06/23 18:36
Carisma Therapeutics, OrthoCellix enter definitive merger agreement
TipRanks · 06/23 17:07
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 06/23 12:08
Carisma Therapeutics, OrthoCellix Agree to Create New Company
Dow Jones · 06/23 11:55
More
About CARM
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on macrophage engineering to develop transformative therapies to treat serious diseases including liver fibrosis and cancer. The Company seeks to apply the ability to engineer macrophages and monocytes, either in vivo or ex vivo. Its proprietary chimeric antigen receptor macrophages(CAR-M) platform uses CARs to redirect macrophages or monocytes against specific tumor associated antigens with the goal of targeted antitumor immunity. It is developing a pipeline of product candidates which includes CT-1119, In Vivo CAR-Macrophage: GPC3+ Solid Tumors, In Vivo CAR-Macrophage: Oncology Targets, and CT-2401 (Liver Fibrosis). CT-2401 is a product candidate in development for liver fibrosis, and CT-1119 is a mesothelin-targeted CAR-Monocyte that is designed to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others.

Webull offers Carisma Therapeutics Inc stock information, including NASDAQ: CARM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CARM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CARM stock methods without spending real money on the virtual paper trading platform.